- Home
- CHX vs BBIO Comparison
CHX vs BBIO Comparison
Compare CHX & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHX
- BBIO
- Stock Information
- Founded
- CHX 1882
- BBIO 2015
- Country
- CHX United States
- BBIO United States
- Employees
- CHX N/A
- BBIO N/A
- Industry
- CHX Industrial Machinery/Components
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- CHX Industrials
- BBIO Health Care
- Exchange
- CHX Nasdaq
- BBIO Nasdaq
- Market Cap
- CHX 5.5B
- BBIO 5.6B
- IPO Year
- CHX N/A
- BBIO 2019
- Fundamental
- Price
- CHX $31.27
- BBIO $36.08
- Analyst Decision
- CHX Buy
- BBIO Strong Buy
- Analyst Count
- CHX 3
- BBIO 13
- Target Price
- CHX $41.33
- BBIO $48.33
- AVG Volume (30 Days)
- CHX 2.2M
- BBIO 2.5M
- Earning Date
- CHX 02-03-2025
- BBIO 02-20-2025
- Dividend Yield
- CHX 1.22%
- BBIO N/A
- EPS Growth
- CHX 7.15
- BBIO N/A
- EPS
- CHX 1.62
- BBIO N/A
- Revenue
- CHX $3,665,501,000.00
- BBIO $217,765,000.00
- Revenue This Year
- CHX N/A
- BBIO $2,309.33
- Revenue Next Year
- CHX $3.96
- BBIO N/A
- P/E Ratio
- CHX $19.16
- BBIO N/A
- Revenue Growth
- CHX N/A
- BBIO 2209.77
- 52 Week Low
- CHX $25.57
- BBIO $21.62
- 52 Week High
- CHX $39.95
- BBIO $41.04
- Technical
- Relative Strength Index (RSI)
- CHX 73.98
- BBIO 73.73
- Support Level
- CHX $27.00
- BBIO $33.73
- Resistance Level
- CHX $28.13
- BBIO $36.24
- Average True Range (ATR)
- CHX 0.86
- BBIO 1.63
- MACD
- CHX 0.55
- BBIO 0.65
- Stochastic Oscillator
- CHX 87.63
- BBIO 97.63
About CHX ChampionX Corporation
ChampionX provides chemical solutions and equipment for onshore and offshore oil and gas production. Its engineering expertise spans the well lifecycle, but the firm maintains a particular focus on the production phase. Key offerings include artificial lift services and drilling technologies, specializing in polycrystalline diamond cutter inserts. ChampionX was formed after Apergy acquired its chemical technologies business from Ecolab in 2020.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.